The price of cancer drugs is too high, an increasingly significant issue in U.S. health care expenditures. In this op-ed for the Washington Post, Hagop Kantarjian, scholar in health policy, explains how to reduce the price of cancer drugs.
Kenneth B. Medlock III , Rachel A. Meidl
Sep 21 2021 | Center for Energy Studies
Gary J. Hale
Sep 21 2021 | Center for the U.S. and Mexico